Abstract: The present invention relates to assays for predicting the presence, absence or development of cancer in an individual, particularly endometrial and ovarian cancer, by determining the methylation status of certain CpGs in a population of DNA molecules in a sample which has been taken from the individual, deriving an index value based on the methylation status of the certain CpGs, and predicting the presence, absence or development of cancer in the individual based on the cancer index value. The invention further relates to a method of treating and/or prevention of cancer in an individual, particularly endometrial and ovarian cancer, the method comprising assessing the presence, absence or development of cancer in an individual by performing the assays of the invention, followed by administering one or more therapeutic treatments or measures to the individual based on the assessment.

Abstract: The present invention relates to methods of determining the presence or absence of certain cancers in a human individual, as well as to related methods to determine the response to therapy against certain cancers in a human individual, in particular ovarian cancer in a woman. Such methods are based on the detection-from (eg cell-free) DNA of said human individual—of one or more methylated (or un-methylated) CpGs being associated with differentially methylated regions (DMRs) of the present invention; such as methylation (or un-methylation) at one or more or all of certain CpGs being associated with such DMRs. Accordingly, such methods have diagnostic, prognostic and/or predictive utility for detecting or managing certain cancers in women or men, in particular ovarian cancer in women.

Abstract: The present invention relates to assays for predicting the presence, absence or development of CIN3 and/or cancer, particularly cervical or endometrial cancer, most preferably cervical cancer, in an individual, particularly cervical and endometrial cancer, by determining the methylation status of certain CpGs in a population of DNA molecules in a sample which has been taken from the individual, deriving an index value based on the methylation status of the certain CpGs, and predicting the presence, absence or development of CIN3 and/or cancer, particularly cervical or endometrial cancer, most preferably cervical cancer, in the individual based on the cancer index value.

Abstract: The present invention relates to assays for predicting the presence, absence or development of breast cancer in an individual, by determining the methyl ati on status of certain CpGs in a population of DNA molecules in a sample which has been taken from the individual, deriving an index value based on the methylation status of the certain CpGs, and predicting the presence, absence or development of breast cancer in the individual based on the breast cancer index value. The invention further relates to a method of treating and/or preventing breast cancer in an individual, the method comprising assessing the presence, absence or development of breast cancer in an individual by performing the assays of the invention, followed by administering one or more therapeutic or preventative treatments or measures to the individual based on the assessment.

Abstract: The present invention relates to methods of identifying the presence of DNA from one or more metastatic breast cancer (mBC) cells in a sample from an individual. The invention also relates to methods of diagnosing metastatic breast cancer (mBC) by identifying the presence of mBC cell DNA in a sample from an individual. The invention also relates to methods of identifying a breast cancer patient as having a poor disease prognosis by identifying the presence of DNA from one or more mBC cells in a sample from an individual. The invention additionally relates to methods of identifying in DNA from an individual the presence of a methylation signature associated with mBC by identifying the presence of DNA from one or more mBC cells in a sample from an individual.

Abstract: The present invention relates to methods of determining the presence or absence of certain cancers in a human individual, as well as to related methods to determine the response to therapy against certain cancers in a human individual, in particular ovarian cancer in a woman. Such methods are based on the detection-from (eg cell-free) DNA of said human individual—of one or more methylated (or un-methylated) CpGs being associated with differentially methylated regions (DMRs) of the present invention; such as methylation (or un-methylation) at one or more or all of certain CpGs being associated with such DMRs. Accordingly, such methods have diagnostic, prognostic and/or predictive utility for detecting or managing certain cancers in women or men, in particular ovarian cancer in women.

Abstract: The present invention relates to methods of determining the presence or absence of an ovarian cancer in a woman, as well as to related methods to determine the response to therapy against ovarian cancer in a woman. Such methods are based on the detection—from cell-free DNA of said woman—of one or more methylated (or un-methylated) CpGs being associated with differentially methylated regions (DMRs) of the present invention;such as methylation (or un-methylation) at one or more or all of certain CpGs being associated with such DMRs. Accordingly, such methods have diagnostic, prognostic and/or predictive utility for detectingor managing ovarian cancer in women.